The characteristics of acceptable preapproval evidence were more flexible for novel drugs approved by the U.S. Food and Drug Administration in 2020, according to a research letter published online May 17 in JAMA Network Open. Mayookha Mitra-Majumdar, M.P.H., from the Brigham and Women’s Hospital and Harvard Medical School in Boston, and colleagues characterized the state of...
